Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Not Yet Opened 01-09 16:00:00 EST

0.6451

-0.0079

-1.21%

盘后0.6300

-0.0151-2.34%

18:58 EST

High0.6692	Low0.6301	Vol893.29K
Open0.6600	D1 Closing0.6530	Amplitude5.99%
Mkt Cap83.33M	Tradable Cap83.28M	Total Shares129.17M
T/O574.52K	T/O Rate0.69%	Tradable Shares129.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":0.6451,"timestamp":1767992400000,"preClose":0.653,"halted":0,"volume":893294,"hourTrading":{"tag":"盘后","latestPrice":0.63,"preClose":0.6451,"latestTime":"18:58 EST","volume":2559,"amount":1631.5576,"timestamp":1768003135566},"delay":0,"floatShares":129099914,"shares":129171424,"eps":-0.234807,"marketStatus":"Not Yet Opened","change":-0.0079,"latestTime":"01-09 16:00:00 EST","open":0.66,"high":0.6692,"low":0.6301,"amount":574522.750735,"amplitude":0.059877,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.234807,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":0.653,"preHourTrading":{"tag":"盘前","latestPrice":0.65,"preClose":0.653,"latestTime":"09:21 EST","volume":8024,"amount":5227.050489,"timestamp":1767968499555},"postHourTrading":{"tag":"盘后","latestPrice":0.63,"preClose":0.6451,"latestTime":"18:58 EST","volume":2559,"amount":1631.5576,"timestamp":1768003135566},"volumeRatio":0.6720001757105474,"impliedVol":1.8561,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2601093818","title":"BRIEF-Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter For (Z)-Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2601093818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601093818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708771,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter For (Z)-Endoxifen Jan 6 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS RECEIVES FDA \"STUDY MAY PROCEED\" LETTER FOR (Z)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2FKRGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2601972758","title":"FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601972758","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601972758?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:15","pubTimestamp":1767705329,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration  for its investigational new drug application of -endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of -endoxifen, a selective estrogen receptor modulator/degrader  with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s -endoxifen is not yet approved for any indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL46cVHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2601897472","title":"Atossa Therapeutics Receives FDA \"Study May Proceed\" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897472?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:15","pubTimestamp":1767705300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2FKRGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2591987649","title":"Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2591987649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591987649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803693,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc., a clinical-stage biopharmaceutical company, presented four clinical trial updates related to its investigational drug -endoxifen at the 2025 San Antonio Breast Cancer Symposium , held December 9-12, 2025. The presentations included initial results from the RECAST DCIS multicenter platform trial, which is evaluating active surveillance and novel endocrine therapy agents for the management of ductal carcinoma in situ . Early pharmacodynamic data indicated that 86% of patients achieved a Week 4 Ki-67 ≤10%, supporting the selection of 40 mg -endoxifen with ovarian function suppression for Phase II studies. The trial is also assessing whether short-term endocrine therapy combined with MRI response assessment can identify DCIS patients suitable for long-term active surveillance and potentially avoid surgery. The findings showed promising antiproliferative efficacy, good tolerability, and steady enrollment, with many patients choosing to continue active surveillance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL5sGPs7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2591846146","title":"Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2591846146","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591846146?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:01","pubTimestamp":1765576888,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced that it will hold a Special Meeting of Stockholders virtually on January 20, 2026. During the meeting, stockholders will be asked to approve a reverse stock split intended to increase the per share trading price of the company's common stock and help maintain its listing on the Nasdaq Stock Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL4dvmpH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2590543348","title":"Why Are Shares Of Atossa Therapeutics Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:26","pubTimestamp":1765473960,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Pharmacy--Pills-And-Tablet-With-Hands-Of.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49341564/why-are-shares-of-atossa-therapeutics-up-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ATOS","BK4079","BK4007","BK4551","Z","BK4585","BK4588","LENZ","BK4548","BK4139","BK4539"],"gpt_icon":0},{"id":"2590516876","title":"FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516876","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516876?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:01","pubTimestamp":1765458117,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has received Rare Pediatric Disease  designation from the U.S. Food and Drug Administration  for its drug candidate -Endoxifen for the treatment of Duchenne Muscular Dystrophy . This regulatory milestone may qualify Atossa for a Priority Review Voucher upon future approval, which could be used for expedited FDA review of another application or sold to another company. The designation recognizes -Endoxifen's potential as a treatment for DMD, a severe childhood neuromuscular disease, and highlights its differentiated mechanism that does not target specific exon defects, potentially broadening its applicability among patients. No other organizations were mentioned as recipients of this regulatory designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL904ncn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2590369349","title":"Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods","url":"https://stock-news.laohu8.com/highlight/detail?id=2590369349","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590369349?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:02","pubTimestamp":1765285339,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. announced the issuance of U.S. Patent No. 12,479,790 B2, titled \"Methods for Making and Using Endoxifen.\" The new patent covers enteric oral formulations of highly pure -endoxifen free base, methods of using these compositions to treat hormone-dependent breast disorders and other estrogen-related conditions, as well as specific solid oral dosage forms and stable formulations that provide sustained systemic exposure to -endoxifen. This patent is expected to strengthen Atossa's intellectual property portfolio supporting its endoxifen therapeutic programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on Dece","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1fjpgk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2590346078","title":"Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346078?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:00","pubTimestamp":1765285206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA3BYZVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2588305342","title":"Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588305342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588305342?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680560,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has announced the publication of a joint study evaluating -endoxifen as a potential therapeutic candidate for glioblastoma multiforme . The results of the study, which utilized Insilico's AI-powered PandaOmics platform to systematically explore new oncology indications for endoxifen, have been published in Nature Scientific Reports. The study identified GBM as a top candidate for further investigation of -endoxifen, an active metabolite of tamoxifen with known activity in endocrine-resistant breast cancer. The announcement did not specify the initiation of a clinical trial, but highlighted the publication of these preclinical findings and the potential for future therapeutic programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3M5N0x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDLR","VIPS","WMT","ATOS","POWL","XP","ACM","BRBR","ENTA","TBBB","AZTA","DE","BBWI","ENR","TGT","BZ","ANRO","CRGO","AS","ATRA","AHL","CLCO","AREC","DLB","ARMK","BULL","BNTC","CPA","EARN","ADIL","ATKR","CRDL","CING","TCOM","CRNC","BMA","CLSD","NTES","CPRT","ZTO","ARBE","ALLT","WB","DY","BV","CGON","NVDA"],"gpt_icon":1},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGT","ATOS","BNZI","BZ","ANRO","AZTA","CDLR","CPA","AHL","DEFT","AREC","BRBR","ACM","CING","BMA","BBAR","BV","POWL","ATAI","DY","CRNC","NTES","ZTO","XP","ATRA","AS","ARMK","DE","DLB","ADIL","LGN","BNTC","TCOM","ARBE","ATKR","ALLT","CLSD","WB","CLCO","BBWI","CGON","BTBT","CRGO","CRDL","NVDA"],"gpt_icon":1},{"id":"2582249371","title":"Atossa Therapeutics Q3 net loss widens as operating costs rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2582249371","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582249371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:24","pubTimestamp":1762953858,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Q3 net loss widens as operating costs riseOverviewAtossa Therapeutics Q3 net loss widens to $8.7 mln, operating expenses rise to $9.3 mlnCompany advances (Z)-endoxifen program with","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2582371628","title":"Atossa Therapeutics Secures Israeli Patent for (Z)-Endoxifen, Strengthening Global IP Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371628","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371628?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953333,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics announced the issuance of a new Israeli patent  titled \"Methods for Making and Using Endoxifen.\" The patent was granted on July 2, 2025, and claims priority to multiple U.S. provisional applications filed in 2017 and 2018. This development marks continued progress in strengthening the company's global intellectual property portfolio for its lead program, -endoxifen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8dpC0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2582371548","title":"Atossa Therapeutics Q3 Pretax Profit USD -8.692 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371548?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXADFDB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2582371544","title":"Atossa Therapeutics Q3 Operating Expenses USD 9.251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371544?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:15","pubTimestamp":1762953301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXADFDB1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2582388013","title":"Top News Today/Canada: Barrick's Interim CEO Gets to Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388013?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"Barrick Looks to Get Handle on North American Operations, Find Growth. Barrick Mining is diving into how its core gold operations in Nevada are being run and is looking for opportunities to boost production, steps that come after parting ways with its former chief executive.Mark Hill, Barrick's interim CEO, said that the mining company is determined to grow and not just replace the resources it digs up, and to produce gold and copper safely.Since taking on the role and being named chief operating officer in late September, Hill said he has met with Barrick's teams around the world. He also spent several weeks in Nevada, which alongside an asset in the Dominican Republic, is a focus of the company's review.Barrick Looking to Reset Safety Culture  Barrick Continues Efforts to Free Workers Jailed in Mali. Burger King Strikes Joint Venture to Double Presence in China. C2AE offers a range of engineering services to clients including state and local governments, transportation agencies, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SND","ACCS","BK4138","LPTH","DOX","IE00BFMHRM44.USD","GNPX","BK4134","CLDX","MGTX","PRLD","QUIK","IPSC","LU0205193047.USD","BK4109","BK4079","BK4137","ATOS","MVIS","BK4179","GIFI","MGNX","EVI","BK4551","CENN","BK4168","ATRA","LU0205194284.USD","SSTI","SYPR","WKHS","NRDE","WHLM","STXS","BK4539","FTHM","BK4082","SLSN","BK4099","NMM","AMTX","CRBU","BK4505","BK4021","KALV","PVLA","BK4547","BK4139","BK4023"],"gpt_icon":1},{"id":"2581884105","title":"Atossa Therapeutics Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884105","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884105?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:21","pubTimestamp":1762528866,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of7cents a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ24Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2577827161","title":"Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2577827161","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577827161?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:00","pubTimestamp":1761048057,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has announced progress in the RECAST platform trial, which is focused on ductal carcinoma in situ , a non-invasive breast condition. The company highlighted enrollment momentum, its biomarker strategy, and plans for near-term data readouts that aim to de-risk development of -Endoxifen and other endocrine therapies for DCIS. Laura J. Esserman, MD, MBA, Principal Investigator of RECAST, will discuss the active-surveillance strategy and novel endocrine agents at the Early Detection Research Conference in Portland, OR. Results from the trial are expected in the future, as interim readout opportunities are anticipated to guide further development and payer-relevant modeling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL4wWWy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2576720999","title":"Health Rounds: Scientists find way to make breast cancer drug work better for younger women","url":"https://stock-news.laohu8.com/highlight/detail?id=2576720999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576720999?lang=en_us&edition=fundamental","pubTime":"2025-10-17 03:38","pubTimestamp":1760643501,"startTime":"0","endTime":"0","summary":"Health Rounds: Scientists find way to make breast cancer drug work better for younger womenHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidOct 16  - Hello Health Rounds readers!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL2N3VV0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":-0.2411},{"period":"3month","weight":-0.4027},{"period":"6month","weight":-0.3126},{"period":"1year","weight":-0.3024},{"period":"ytd","weight":0.0934}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.279542},{"month":2,"riseRate":0.538462,"avgChangeRate":0.099322},{"month":3,"riseRate":0.384615,"avgChangeRate":0.084638},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.043139},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.014461},{"month":6,"riseRate":0.615385,"avgChangeRate":0.128869},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction